These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 27097386)
1. [Invasive closure of patent foramen ovale without benefits]. Pommer P Dtsch Med Wochenschr; 2016 Jan; 141(1):16. PubMed ID: 27097386 [No Abstract] [Full Text] [Related]
2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial. Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L; JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037 [TBL] [Abstract][Full Text] [Related]
3. The paradox of paradoxical embolism and recurrent stroke. Abou-Chebl A JACC Cardiovasc Interv; 2014 Aug; 7(8):921-2. PubMed ID: 25147038 [No Abstract] [Full Text] [Related]
4. Expanding the armamentarium for effective PFO closure. Jumean M; Kimmelstiel C Catheter Cardiovasc Interv; 2015 Jun; 85(7):1268-9. PubMed ID: 25999279 [No Abstract] [Full Text] [Related]
5. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929 [TBL] [Abstract][Full Text] [Related]
6. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis. Shah SR Clin Res Cardiol; 2019 Apr; 108(4):452. PubMed ID: 30374773 [No Abstract] [Full Text] [Related]
7. Patent foramen ovale and cryptogenic stroke. Messé SR; Kent DM N Engl J Med; 2013 Jul; 369(1):92-3. PubMed ID: 23833785 [No Abstract] [Full Text] [Related]
9. Patent foramen ovale and cryptogenic stroke. Wood WC; Switchenko JM N Engl J Med; 2013 Jul; 369(1):88. PubMed ID: 23822783 [No Abstract] [Full Text] [Related]
10. Still no closure on the question of PFO closure. Messé SR; Kent DM N Engl J Med; 2013 Mar; 368(12):1152-3. PubMed ID: 23514293 [No Abstract] [Full Text] [Related]
11. Patent Foramen Ovale after Cryptogenic Stroke - Assessing the Evidence for Closure. Farb A; Ibrahim NG; Zuckerman BD N Engl J Med; 2017 Sep; 377(11):1006-1009. PubMed ID: 28902595 [No Abstract] [Full Text] [Related]
14. Recurrent embolic events after PFO closure: how often and why? Moussa ID Catheter Cardiovasc Interv; 2013 Oct; 82(4):547-8. PubMed ID: 24078416 [No Abstract] [Full Text] [Related]
15. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack. Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394 [TBL] [Abstract][Full Text] [Related]
16. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study. Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661 [TBL] [Abstract][Full Text] [Related]